Randomized trial · people
Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people on oral semaglutide, this head-to-head trial found it lowered HbA1c less than orforglipron over a year, but with fewer gut side effects and fewer people stopping treatment.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1698
- Published
- 2026
- Journal
- Lancet
What they tested
Does daily oral orforglipron lower blood sugar at least as well as daily oral semaglutide in adults with type 2 diabetes whose sugar stayed too high on metformin?
How the study was done
A randomized, open-label (everyone knew which drug they got) phase 3 trial of 1698 adults with type 2 diabetes on metformin, at 131 sites in Argentina, China, Japan, Mexico and the USA. People were assigned to one of four daily pills for 52 weeks: orforglipron 12 mg or 36 mg, or oral semaglutide 7 mg or 14 mg.

Model. Individual results vary.
What they found
From a starting HbA1c (a 3-month average of blood sugar) of 8.3%, the average change at 52 weeks was -1.23% in the semaglutide 7 mg arm and -1.47% in the 14 mg arm, against -1.71% with orforglipron 12 mg and -1.91% with orforglipron 36 mg. Both orforglipron doses beat both semaglutide doses; for example, orforglipron 36 mg versus semaglutide 14 mg differed by -0.44% (95% CI -0.62 to -0.26). Stomach and gut side effects, mostly mild to moderate, hit 37% and 45% of the semaglutide arms versus 59% and 58% of the orforglipron arms. Fewer people quit semaglutide because of side effects (4% and 5%, versus 9% and 10%), and pulse rose less on semaglutide (1.0 and 1.5 bpm, versus 3.7 and 4.7 bpm).
What it doesn’t show
Participants and staff knew which drug was given, the trial ran 52 weeks, and it only included people already taking metformin. The trial was funded by Eli Lilly.
The paper
Rosenstock et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026.
The compounds
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UPRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.